SCHEMBL26998207

SCHEMBL26998207

CN(CCCO)c1cc(-c2cn[nH]c2)c2ccc(Cl)c(Cl)c2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K14 Q99558 2/20 0.37
▸ ROCK2 O75116 9/20 0.37
▸ FGFR1 P11362 4/20 0.35
▸ FGFR2 P21802 4/20 0.35
▸ FGFR4 P22455 4/20 0.35
▸ FGFR3 P22607 4/20 0.35
▸ KDR P35968 4/20 0.35
▸ FLT3 P36888 2/20 0.35
▸ ROCK1 Q13464 4/20 0.33
▸ PRKAB2 O43741 1/20 0.33
▸ PRKAG1 P54619 1/20 0.33
▸ PRKAA2 P54646 1/20 0.33
▸ PRKAA1 Q13131 1/20 0.33
▸ PRKAG3 Q9UGI9 1/20 0.33
▸ PRKAG2 Q9UGJ0 1/20 0.33
▸ PRKAB1 Q9Y478 1/20 0.33
▸ PIM1 P11309 1/20 0.32
▸ PIM2 Q9P1W9 1/20 0.32
▸ AKT1 P31749 1/20 0.32
▸ CHUK O15111 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26998196 0.94 MAP3K14 (0.38) MAP3K14ROCK2FGFR1FGFR2FGFR4
SCHEMBL26999118 0.88 PTPN11 (0.40) MAP3K14ROCK2FGFR1FGFR2FGFR4
SCHEMBL25424012 0.86 MAP3K14 (0.38) MAP3K14ROCK2ROCK1
SCHEMBL26998214 0.86 MAP3K14 (0.35) MAP3K14ROCK2ROCK1
SCHEMBL26998160 0.85 MAP3K14 (0.36) MAP3K14ROCK2ROCK1
SCHEMBL26998152 0.85 MAP3K14 (0.36) MAP3K14ROCK2ROCK1
SCHEMBL26998155 0.84 ROCK2 (0.36) MAP3K14ROCK2ROCK1PRKAB2PRKAG1
SCHEMBL26998153 0.84 ROCK2 (0.36) MAP3K14ROCK2ROCK1
SCHEMBL25427115 0.82 MAP3K14 (0.38) MAP3K14ROCK2ROCK1PIM1PIM2
SCHEMBL25423156 0.82 AKT1 (0.39) ROCK2FGFR1FGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS MAP3K14 2494/4885ROCK2 1771/4885FGFR1 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback